![]() These states had the largest increase in median drive time: The percentage of those ages 10 to 17 who live more than an hour’s drive from a clinic offering gender-affirming drugs grew from 27.2 percent to 50 percent because of state restrictions, the researchers found. The researchers accounted for clinics in states where gender-affirming care for minors is restricted. University of Michigan researchers calculated the median time it would take in each state to drive, with no traffic, to the nearest clinic offering gender-affirming drugs. Youth seeking gender-affirming care must drive significantly longer to access it as laws barring the prescription of hormones or surgery to minors are passed in states, a new analysis has found. Getting transgender care is getting harder in much of the country. It’s widely expected that the most controversial items will be removed during negotiations, allowing the bill to become law, as it has for 62 straight years. The House bill included myriad controversial provisions, including some on abortion and transgender care, pushed by the socially conservative wing of the GOP. What’s next? Senators must reconcile their version of the National Defense Authorization Act with the one the House passed on a party-line vote earlier this month. A pilot program to assess the feasibility and advisability of building up the Mexican military’s capacity to counter drug cartels A directive for the secretary of Defense to create a plan to disrupt fentanyl trafficking A requirement for an annual report on military overdoses, both fatal and nonfatal Establishment of a program to treat service members for PTSD and other disorders related to military sexual trauma Coverage of assisted reproductive technology (but not in-vitro fertilization) for service members and dependents It contains several significant health care provisions that could make it into law: The Senate passed its annual defense policy bill by a wide, bipartisan margin before skipping town for Congress’ August recess last week. Senate leaders found common cause in passing the annual defense policy bill last week. The firm is exploring emergency use authorization and expedited FDA processes to get it there faster. What’s next? If all goes well, the treatment could be on the market by the end of 2025, Woody said. But ensuring more frequent visits with providers is good for patients, she said. “This not only protects you from an overdose, but it also shuts down any euphoric feeling that you would get from fentanyl,” CEO Tracy Woody said, making quitting easier.Įven so: Patients would have to see a doctor monthly to get the drug, which could slow uptake. In primates, it’s worked with fentanyl analogs and has extinguished drug-taking behavior over time.ĬEO Tracy Woody said if trials succeed and the treatment hits the market, she expects it will not only reduce overdoses, but also help people quit. “It’s there to sequest fentanyl, to sort of Pac-Man fentanyl up before it can ever get to the brain,” said Andy Barrett, the firm’s chief scientific officer. That should protect fentanyl users from some of the drug’s effects, like respiratory depression, that can cause fatal overdoses. ![]() Hong/AP PhotoĬlinical trials are set to begin this month on a novel fentanyl-addiction therapy that its maker hopes will crush the curve of fatal fentanyl overdoses, now cresting at around 70,000 a year.Ĭessation Therapeutics, of Chapel Hill, N.C., has the Food and Drug Administration’s approval to begin testing its monoclonal antibody that aims to prevent fentanyl from reaching the brain. There's a new plan to help people addicted to fentanyl.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |